Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)

NCT04286438 is registered in ClinicalTrials.gov with SFJ Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04286438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04286438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
Lead sponsor
SFJ Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 15, 2020
Completion date
September 9, 2024
Enrollment
226 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

hemorrhage, invasive procedure, urgent surgery